[go: up one dir, main page]

DE102005011003A1 - Differentiating between different forms of malignant and benign thyroid tumors, based on altered expression of selected genes in thyroid tissue - Google Patents

Differentiating between different forms of malignant and benign thyroid tumors, based on altered expression of selected genes in thyroid tissue Download PDF

Info

Publication number
DE102005011003A1
DE102005011003A1 DE102005011003A DE102005011003A DE102005011003A1 DE 102005011003 A1 DE102005011003 A1 DE 102005011003A1 DE 102005011003 A DE102005011003 A DE 102005011003A DE 102005011003 A DE102005011003 A DE 102005011003A DE 102005011003 A1 DE102005011003 A1 DE 102005011003A1
Authority
DE
Germany
Prior art keywords
benign
thyroid
differentiating
malignant
different forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE102005011003A
Other languages
German (de)
Other versions
DE102005011003B9 (en
DE102005011003B4 (en
Inventor
Ralf Paschke
Markus Eszlinger
Knut Krohn
Dagmar Fuehrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Leipzig
Original Assignee
Universitaet Leipzig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Leipzig filed Critical Universitaet Leipzig
Priority to DE102005011003A priority Critical patent/DE102005011003B9/en
Publication of DE102005011003A1 publication Critical patent/DE102005011003A1/en
Application granted granted Critical
Publication of DE102005011003B4 publication Critical patent/DE102005011003B4/en
Publication of DE102005011003B9 publication Critical patent/DE102005011003B9/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Differentiating between benign and malignant tumors of the thyroid comprising isolating RNA from thyroid tissue and quantifying mRNA transcripts, is new. Differentiating between benign and malignant tumors of the thyroid comprises isolating RNA from thyroid tissue and quantifying mRNA transcripts from at least one of 153 genes (all listed by name and NCBI accession number). An increase in transcripts from 18 of these genes, or a reduction in transcripts from 14 of them indicates a benign tumor, while an increase from 77 of them or reduction from 52 of them indicates a malignant tumor. Independent claims are also included for: (1) differentiating any one of benign hot nodules, benign cold nodules, malignant follicular carcinoma and maligant papillar carcinoma from the other three; (2) diagnostic kit for the new processes; and (3) hybridization probes (SEQ ID NO.19) and (SEQ ID NO.20).
DE102005011003A 2004-03-03 2005-03-03 Method and means for the differential diagnosis of thyroid tumors Expired - Fee Related DE102005011003B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102005011003A DE102005011003B9 (en) 2004-03-03 2005-03-03 Method and means for the differential diagnosis of thyroid tumors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004011623.7 2004-03-03
DE102004011623 2004-03-03
DE102005011003A DE102005011003B9 (en) 2004-03-03 2005-03-03 Method and means for the differential diagnosis of thyroid tumors

Publications (3)

Publication Number Publication Date
DE102005011003A1 true DE102005011003A1 (en) 2005-10-20
DE102005011003B4 DE102005011003B4 (en) 2008-07-31
DE102005011003B9 DE102005011003B9 (en) 2009-02-26

Family

ID=35034240

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005011003A Expired - Fee Related DE102005011003B9 (en) 2004-03-03 2005-03-03 Method and means for the differential diagnosis of thyroid tumors

Country Status (1)

Country Link
DE (1) DE102005011003B9 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10118452A1 (en) * 2001-04-12 2002-10-31 Joern Bullerdiek Nucleic acid sequences from hyperplasias and thyroid tumors

Also Published As

Publication number Publication date
DE102005011003B9 (en) 2009-02-26
DE102005011003B4 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
Singh et al. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas
Wiklund et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma
WO2008063769A3 (en) Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
Yang et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP2444505A3 (en) Urine markers for detection of bladder cancer
Christoph et al. Regularly methylated novel pro‐apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder
Raghunandan et al. Expression of human telomerase reverse transcriptase protein in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical study
WO2004035806A3 (en) Methods and nucleic acids for the analysis of cpg dinucleotide methylation status associated with the calcitonin gene
Perry et al. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
Ruan et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1
Syrenicz et al. New insights into the diagnosis of nodular goiter
Si et al. Hepatocellular lymphoepithelioma-like carcinoma associated with epstein barr virus: a hitherto unrecognized entity
Wang et al. XRCC1 downregulated through promoter hypermethylation is involved in human gastric carcinogenesis
Reicher et al. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses
DE102005011003A1 (en) Differentiating between different forms of malignant and benign thyroid tumors, based on altered expression of selected genes in thyroid tissue
WO2000056924A3 (en) Genomic sequence of the purh gene and purh-related biallelic markers
Hinz et al. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder
Egawa et al. High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients
Ye et al. Decreased expression of insulin-like growth factor binding protein 7 in human colorectal carcinoma is related to DNA methylation
Naser et al. Currently used and new molecular markers for thyroid cancer diagnosis
Huang et al. Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8364 No opposition during term of opposition
8397 Reprint of erroneous patent document
8339 Ceased/non-payment of the annual fee